 Simeprevir
"Simeprevir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.
| Descriptor ID |
D000069616
|
| MeSH Number(s) |
D02.886.590.700.700 D03.633.300.819
|
| Concept/Terms |
Simeprevir- Simeprevir
- N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide
TMC 435350- TMC 435350
- 435350, TMC
- TMC435350
- TMC-435350
TMC 435- TMC 435
- 435, TMC
- TMC435
- TMC-435
|
Below are MeSH descriptors whose meaning is more general than "Simeprevir".
Below are MeSH descriptors whose meaning is more specific than "Simeprevir".
This graph shows the total number of publications written about "Simeprevir" by people in this website by year, and whether "Simeprevir" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 2 | 0 | 2 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Simeprevir" by people in Profiles.
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
-
Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Harrington LA, Lin S, Ghuschcyan V, Nair KV, Everson GT. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. Ann Hepatol. 2017 May - Jun; 16(3):366-374.
-
Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol. 2017 Mar 07; 23(9):1618-1626.
-
Jackson WE, Hanouneh M, Apfel T, Alkhouri N, John BV, Zervos X, Zein NN, Hanouneh IA. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience. Clin Transplant. 2016 Jun; 30(6):709-13.
-
Brown RS, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|